Associations - EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)

EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1
EZH2 mutation	Acute Myelogenous Leukemia	EZH2 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	tazemetostat Sensitive: C1 - Off-label tazemetostat Sensitive : C1	tazemetostat Sensitive: C1 - Off-label tazemetostat Sensitive : C1
EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	valemetostat Sensitive: C2 – Inclusion Criteria valemetostat Sensitive : C2	valemetostat Sensitive: C2 – Inclusion Criteria valemetostat Sensitive : C2
EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3
EZH2 mutation	Myelodysplastic Syndrome	EZH2 mutation	Myelodysplastic Syndrome	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
EZH2 overexpression	Mediastinal B Cell Lymphoma	EZH2 overexpression	Mediastinal B Cell Lymphoma	lisocabtagene maraleucel Resistant: C3 – Early Trials lisocabtagene maraleucel Resistant : C3	lisocabtagene maraleucel Resistant: C3 – Early Trials lisocabtagene maraleucel Resistant : C3
EZH2 mutation + BCL2 translocation	Diffuse Large B Cell Lymphoma	EZH2 mutation + BCL2 translocation	Diffuse Large B Cell Lymphoma	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3
EZH2 rs201135441C>T	Estrogen Receptor Positive Breast Cancer	EZH2 rs201135441C>T	Estrogen Receptor Positive Breast Cancer	tamoxifen Resistant: C3 – Early Trials tamoxifen Resistant : C3	tamoxifen Resistant: C3 – Early Trials tamoxifen Resistant : C3
EZH2 A490T	Breast Cancer	EZH2 A490T	Breast Cancer	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3
EZH2 underexpression	Rectal Cancer	EZH2 underexpression	Rectal Cancer	capecitabine Sensitive: C3 – Early Trials capecitabine Sensitive : C3	capecitabine Sensitive: C3 – Early Trials capecitabine Sensitive : C3
EZH2 underexpression	Soft Tissue Sarcoma	EZH2 underexpression	Soft Tissue Sarcoma	nivolumab + sunitinib Sensitive: C3 – Early Trials nivolumab + sunitinib Sensitive : C3	nivolumab + sunitinib Sensitive: C3 – Early Trials nivolumab + sunitinib Sensitive : C3

EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)

Associations(38)

Associations
(38)